先声药业(02096)：SIM0237于2026年欧洲泌尿外科学会年会公布非肌层浸润性膀胱癌的I/II期临床研究数据

智通财经03-17

智通财经APP讯，先声药业(02096)发布公告，本集团自主研发的创新融合蛋白 SIM0237(PD-L1/IL15v双特异性抗体)于2026年欧洲泌尿外科学会年会(EAU 2026)公布用于治疗卡介苗(BCG)无应答高危非肌层浸润性膀胱癌(NMIBC)的I/II 期临床研究数据。截至数据截止日(2025年11月28日)，共有49名患者接受SIM0237单药膀胱灌注治疗。在伴原位癌(CIS)且至少...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2620425231?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2026-03-17 18:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2620425231","market":"hk","top_or_hot":-1,"title":"先声药业(02096)：SIM0237于2026年欧洲泌尿外科学会年会公布非肌层浸润性膀胱癌的I/II期临床研究数据","media":"智通财经","content":"<div>\n<p>智通财经APP讯，先声药业(02096)发布公告，本集团自主研发的创新融合蛋白 SIM0237(PD-L1/IL15v双特异性抗体)于2026年欧洲泌尿外科学会年会(EAU 2026)公布用于治疗卡介苗(BCG)无应答高危非肌层浸润性膀胱癌(NMIBC)的I/II 期临床研究数据。截至数据截止日(2025年11月28日)，共有49名患者接受SIM0237单药膀胱灌注治疗。在伴原位癌(CIS)且至少...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414977.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>先声药业(02096)：SIM0237于2026年欧洲泌尿外科学会年会公布非肌层浸润性膀胱癌的I/II期临床研究数据</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n先声药业(02096)：SIM0237于2026年欧洲泌尿外科学会年会公布非肌层浸润性膀胱癌的I/II期临床研究数据\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-17 18:45 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/1414977.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP讯，先声药业(02096)发布公告，本集团自主研发的创新融合蛋白 SIM0237(PD-L1/IL15v双特异性抗体)于2026年欧洲泌尿外科学会年会(EAU 2026)公布用于治疗卡介苗(BCG)无应答高危非肌层浸润性膀胱癌(NMIBC)的I/II 期临床研究数据。截至数据截止日(2025年11月28日)，共有49名患者接受SIM0237单药膀胱灌注治疗。在伴原位癌(CIS)且至少...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/1414977.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02096","symbol_name":"先声药业","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/1414977.html","article_id":"2620425231","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2620425231","pubTimestamp":1773744323,"columns":[],"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP讯，先声药业 发布公告，本集团自主研发的创新融合蛋白 SIM0237于2026年欧洲泌尿外科学会年会公布用于治疗卡介苗无应答高危非肌层浸润性膀胱癌的I/II 期临床研究数据。截至数据截止日，共有49名患者接受SIM0237单药膀胱灌注治疗。整体结果显示SIM0237在BCG无应答高危NMIBC患者中展现出具有前景的临床疗效信号。安全性方面，SIM0237膀胱灌注给药显示出良好的安全性及耐受性，且血清样本分析未检测到药物的系统性暴露。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"02096":"先声药业","BK1191":"制药","BK1583":"高瓴概念"},"translate_title":"Simcere Pharmaceuticals (02096): SIM0237 Announces Phase I/II Clinical Study Data for Non-Muscle Invasive Bladder Cancer at the 2026 European Society of Urology Annual Meeting","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02096":1.5},"content_text":"智通财经APP讯，先声药业(02096)发布公告，本集团自主研发的创新融合蛋白 SIM0237(PD-L1/IL15v双特异性抗体)于2026年欧洲泌尿外科学会年会(EAU 2026)公布用于治疗卡介苗(BCG)无应答高危非肌层浸润性膀胱癌(NMIBC)的I/II 期临床研究数据。截至数据截止日(2025年11月28日)，共有49名患者接受SIM0237单药膀胱灌注治疗。在伴原位癌(CIS)且至少完成一次基线后肿瘤评估的患者中，80%的患者达到完全缓解(CR)。在仅伴乳头状病变的患者中，12个月无病生存率(DFS)为 65.8%。整体结果显示SIM0237在BCG无应答高危NMIBC患者中展现出具有前景的临床疗效信号。安全性方面，SIM0237膀胱灌注给药显示出良好的安全性及耐受性，且血清样本分析未检测到药物的系统性暴露。","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences,dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.42.0","shortVersion":"4.42.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2620425231","isCrawlerRequest":true}